Accord Zoledronic 4

Accord Zoledronic 4

zoledronic acid


Accord Healthcare


Concise Prescribing Info
Zoledronic acid
Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone or tumour-induced hypercalcemia) in adult patients w/ advanced malignancies involving bone. Treatment of tumour-induced hypercalcaemia (TIH).
Dosage/Direction for Use
Adult & older patient Prevention of skeletal related events in patient w/ advanced malignancies involving bone 4 mg every 3-4 wk. Treatment of TIH Albumin-corrected serum Ca ≥12 mg/dL or 3 mmol/L 4 mg as a single dose.
Pregnancy & lactation.
Special Precautions
Ensure patient is adequately hydrated. Avoid overhydration in patients at risk of cardiac failure. Monitor standard hypercalcaemia-related metabolic parameters eg, serum levels of Ca, phosphate & Mg; untreated hypercalcaemia patients w/ some degree of renal function impairment. Do not use concomitantly w/ other bisphosphonate.
Adverse Reactions
Bone pain, fever, fatigue, arthralgia, myalgia, rigors & arthritis w/ subsequent joint swelling. Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, ocular adverse events, atrial fibrillation, anaphylaxis.
Drug Interactions
May cause lower serum Ca levels w/ aminoglycosides. Possibility of developing hypomagnesaemia w/ other potentially nephrotoxic medicines. Risk of renal dysfunction w/ thalidomide in multiple myeloma patients. Increased incidence of ONJ w/ anti-angiogenic medicines.
ATC Classification
M05BA08 - zoledronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.
Accord Zoledronic 4 conc for infusion 4 mg/5 mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in